A Phase II, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation

Brief Summary

Type:
Colorectal

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT06106308

Study #:
STUDY00160166

Start Date:
Mar 31, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06106308

View Complete Trial Details & Eligibility at ClinicalTrials.gov